AURC Company Profile

Among many corporations, the Aslan Pharmaceuticals Limited announced as well its fourth quarter of 2022 results

The shareholders haven't expected some changes at the business during the the October to December 31 2022 reporting cycle at the ASLN. Yet, they consider the company's operating deficit which has been at $-47.882487 millions, during the same period.

Deficit on Weak Sales the company during the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 First Seacoast Bancorp Inc slipped into shortfall of $-0.28 per share compare to $0.07 a year ago and earnings per share fell from $0.08 per share from the prior reporting season.

Sales decreased substantially by -13.143 % to $3.23 millions from $3.71 millions in the same reporting season a year ago and sequentially Sales fell by -23.488 % from $4.22 millions.

PHI announced mixed results in the fourth quarter of 2022 earnings season, where Sales rose by 6.203 % to $3.92 billions compared to $3.70 billions on a year-over-year basis, while EPS dived by -60.36 % to $0.92 per share, from $2.33 in the prior year financial reporting period.

Alluring achievement by the company during the fiscal span closing Dec 31 2022

HGBL delivered very strong results in the fourth quarter of 2022 financial report, where Sales soared by 83.825 % to $13.83 millions, while HGBLs' net profit per share soared by 895.94 % to $0.27 per share, from the same quarter a year prior.

Exceptional 29.494%, gain in Sales by BSBK in the fiscal time-frame ending December 31 2022

BSBK showed respectable improvement in the fourth quarter of 2022, where EPS grown rapidly by 213.02 % year on year to $0.22 per share and Sales increased by 29.494 % to $7.03 millions.